CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
Open accessThe DOI matches its Crossref record; 47 of the 50 references it cites were found in a registry or an index.
Abstract
CTL-associated antigen 4 (CTLA4) blockade releases inhibitory controls on T cell activation and proliferation, inducing antitumor immunity in both preclinical and early clinical trials. We examined the mechanisms of action of anti-CTLA4 and a GM-CSF-transduced tumor cell vaccine (Gvax) and their impact on the balance of effector T cells (Teffs) and Tregs in an in vivo model of B16/BL6 melanoma. Tumor challenge increased the frequency of Tregs in lymph nodes, and untreated tumors became infiltrated by CD4+Foxp3- and CD4+Foxp3+ T cells but few CD8+ T cells. Anti-CTLA4 did not deplete Tregs or permanently impair their function but acted in a cell-intrinsic manner on both Tregs and Teffs, allowing them to expand, most likely in response to self antigen. While Gvax primed the tumor-reactive Teff compartment, inducing activation, tumor infiltration, and a delay in tumor growth, the combination with CTLA4 blockade induced greater infiltration and a striking change in the intratumor balance of Tregs and Teffs that directly correlated with tumor rejection. The data suggest that Tregs control both CD4+ and CD8+ T cell activity within the tumor, highlight the importance of the intratumor ratio of effectors to regulators, and demonstrate inversion of the ratio and correlation with tumor rejection during Gvax/anti-CTLA4 immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“anti-CTLA-4 and anti-PD-1 antibodies have been successful in depleting tumor-infiltrating Tregs and increasing the effector T cell (Teff) to Treg ratio in the tumor microenvironment (Curran et al., 2010; Quezada et al., 2006; Simpson et al., 2013).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Quezada et al., 2006
Experimental — accuracy not yet measuredIn the citing paper
“Mouse melanoma models, for example, have shown that the combination of anti-CTLA-4 with cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF) or with agonistic antibodies targeting costimulatory receptors such as CD40, increased tumor rejection in a synergistic manner (121, 122).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [121]
In the citing paper
“In general, anti-CTLA4 expands CD4 effector T cells (Teff) with subsequent increase in the Teff/ Treg ratio in responding tumors (22).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Sakaguchi, S. (2005) · Nature Immunology · doi:10.1038/ni1178 · Cited by 2,669
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Read, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Cited by
Items 301–400 of 697
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma
Firestone, R., McAvoy, D. P., Shekarkhand, T., Serrano, E., Hamadeh, I. S., Wang, A., Zhu, M., Qin, W. G., Patel, D., Tan, C. R. C., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011225 · Cited by 59
“36 In contrast, patients who did not respond to teclistamab had increased fractions of Tregs and CD4 + TCMs, which can be similarly engaged by the CD3 binding arm of teclistamab.”
BackgroundRoadmap to a Better Therapeutic Tumor Vaccine
Emens, L. A. (2006) · International Reviews of Immunology · doi:10.1080/08830180600992423 · Cited by 61
An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides
Eggink, L. L., Roby, K. F., Cote, R., & Hoober, J. K. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0339-5 · Cited by 60
“Activation of the phagocytic activity of macrophages leads to reduction of TREG cells in melanoma tumors [92, 93].”
BackgroundWatanabe, T., Ishino, T., Ueda, Y., Nagasaki, J., Sadahira, T., Dansako, H., Araki, M., & Togashi, Y. (2023) · Cancer Science · doi:10.1111/cas.15756 · Cited by 60
Kim, H. S., Kim‐Schulze, S., Kim, D. W., & Kaufman, H. L. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2522 · Cited by 56
“There are studies that the balance of effector CD8 T cells to regulatory CD4FoxP3 T cells is the critical determinant of tumor rejection (44, 45).”
Arias, D. A. A., Kim, H. J., Zhou, P., Holderried, T. A. W., Wang, X., Dranoff, G., & Cantor, H. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0121 · Cited by 57
Tian, H., Shi, G., Wang, Q., Li, Y., Yang, Q., Li, C., Yang, G., Wu, M., Xie, Q., Zhang, S., et al. (2016) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2016.25 · Cited by 54
Hu‐Lieskovan, S., & Ribas, A. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000246 · Cited by 55
“In preclinical mouse models, combination of GVAX with CTLA-4 or PD-1(75,76) or both(77) checkpoint inhibitors promoted tumor eradication and survival of the treated animals, with increased CD8 cell infiltration and CD8/Treg ratio in these tumors.(78) Early-phase clinical trial combining GVAX with ipilimumab for patien…”
BackgroundHutmacher, C., Núñez, N. G., Liuzzi, A. R., Becher, B., & Neri, D. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0566 · Cited by 60
“The features of lymphocytes in secondary lymphoid organs were substantially different compared to tumor-infiltrating lymphocytes (TILs), in keeping with recent reports published with other therapeutic modalities (34,40).”
ResultMartori, C., Sánchez-Moral, L., Paul, T., Pardo, J. C., Pous, A. F., de Porras, V. R., & Sarrias, M. (2022) · Cancers · doi:10.3390/cancers14020440 · Cited by 53
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Michielin, O. A., Lalani, A. A., Robert, C., Sharma, P., & Peters, S. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003024 · Cited by 64
“32 33 New benchmarks have been established with improved long-term survival and durable responses in significant proportions of patients, 34–37 with the potential for TFS. Survival benefits can be challenging to quantify, especially in trials with initial reporting based on short follow-up.”
Mallick, A., Barik, S., Goswami, K. K., Banerjee, S., Ghosh, S., Sarkar, K., Bose, A., & Baral, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0047434 · Cited by 51
“In association with type 1 T-cell polarization, effective cancer immunotherapies have been largely associated with an increased T effector-to-Treg ratio [30,31].”
BackgroundImmunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some
Rowdo, F. P. M., Barón, A., Urrutia, M., & Mordoh, J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00127 · Cited by 55
“4× 106 TIL per gram of tumor tissue (approximately 109 tumor cells) (7), though it is difficult to explain how this effector/target ratio (1/1000) could achieve tumor regression.”
BackgroundPuca, E., Probst, P., Stringhini, M., Murer, P., Pellegrini, G., Cazzamalli, S., Hutmacher, C., Gouyou, B., Wulhfard, S., Matasci, M., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32603 · Cited by 51
“These biopharmaceuticals can be considered as “foundational drugs”, to which other therapeutic regimens may be added, in order to achieve optimal anticancer activity.(4,5) In particular, inhibition of the PD-1/PD-L1 axis may help reverse an exhausted phenotype in CD8 T cells, which have previously encountered tumor-as…”
BackgroundNanobodies as non-invasive imaging tools
Rashidian, M., & Ploegh, H. L. (2020) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2020.07.001 · Cited by 57
Kandalaft, L. E., Motz, G. T., Duraiswamy, J., & Coukos, G. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9289-9 · Cited by 58
“In addition, recent studies in mice aimed for boosting effector function of tumor reactive T cells using combinatorial treatment to release endogenous tumor/self-reactive T cells from negative regulatory checkpoints [83, 84, 85].”
BackgroundYi, H., Guo, C., Yu, X., Gao, P., Qian, J., Zuo, D., Manjili, M. H., Fisher, P. B., Subjeck, J. R., & Wang, X. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1801 · Cited by 50
“As a result, the increased ratios of infiltrating CD8þ and CD4þ Teffs to Tregs in the tumor compartment could contribute to the enhanced antitumor efficacy augmented by SRA/CD204-silenced DC vaccine, because the intratumoral balance of Teffs and Tregs has been shown to directly correlate with tumor suppression (31).”
Hekim, C., Ilander, M. M., Yan, J., Michaud, E., Smykla, R. A., Vähä-Koskela, M. J. V., Savola, P., Tähtinen, S., Saikko, L., Hemminki, A., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0061-t · Cited by 51
Yu, G., Mao, L., Wu, L., Deng, W., Bu, L., Liu, J., Chen, L., Yang, L., Wu, H., Zhang, W., et al. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2863-3 · Cited by 52
Arginine methylation of FOXP3 is crucial for the suppressive function of regulatory T cells
Kagoya, Y., Saijo, H., Matsunaga, Y., Guo, T., Saso, K., Anczurowski, M., Wang, C.-H., Sugata, K., Murata, K., Butler, M. O., et al. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.09.011 · Cited by 55
Gao, J., He, Q., Subudhi, S., Aparicio, A., Zurita-Saavedra, A., Lee, D. H., Jimenez, C., Suarez-Almazor, M., & Sharma, P. (2015) · Oncogene · doi:10.1038/onc.2015.5 · Cited by 49
“Monoclonal antibodies that block the immune checkpoint molecule, CTLA-4, have been shown to potentiate T cell activation against a variety of tumors [1, 3, 7, 8].”
BackgroundTowards Curative Cancer Immunotherapy: Overcoming Posttherapy Tumor Escape
Zhou, G., & Levitsky, H. I. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/124187 · Cited by 63
“Anti-CTLA-4 antagonist mAb (ipilimumab) does not reduce Treg cell numbers but instead preferentially exclude Tregs from the tumor lesion, so as to increase the intratumoral Teffector/Treg ratio and improve therapeutic efficacy [75, 76].”
BackgroundTsai, K. K., Huang, S., Northey, J. J., Liao, W., Hsu, C., Cheng, L., Werner, M. E., Chuu, C., Chatterjee, C., Lakins, J. N., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00375-0 · Cited by 59
Zhou, R., Yu, H., Sheng, T., Wu, Y., Chen, Y., You, J., Yang, Y., Luo, B., Zhao, S., Zheng, Y., et al. (2024) · Advanced Materials · doi:10.1002/adma.202401667 · Cited by 54
Immunological Insights from Patients Undergoing Surgery on Ipilimumab for Metastatic Melanoma
Gyorki, D. E., Yuan, J. D., Mu, Z., Zaidi, B., Pulitzer, M. P., BUSAM, K. J., Brady, M. S., Coit, D. G., Allison, J. P., Wolchok, J. D., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-2999-1 · Cited by 51
“also have suggested that a response to CTLA-4 blockade is related to the intratumoral balance of effector T cells (T eff) and regulatory T cells (T reg).(7) T regs function to inhibit the immune system, and increased numbers of T regs have been found in patients with melanoma, suggesting an important role in preventin…”
BackgroundSilva, P. D., Aiello, M. M., Gu‐Trantien, C., Migliori, E., Willard-Gallo, K. E., & Solinas, C. (2020) · International Journal of Cancer · doi:10.1002/ijc.33415 · Cited by 50
“To this end, the size of CD8+ clonal expansion has been found to precede such events, suggesting their detection in the peripheral circulation could represent a potential correlative biomarker.94 The second element provid- ing the rationale for CTLA-4 ICB is the proposed negative effect on immune suppressive Tregs.”
BackgroundInfluentialResistance to immune checkpoint inhibitors and the tumor microenvironment
Kawashima, S., & Togashi, Y. (2022) · Experimental Dermatology · doi:10.1111/exd.14716 · Cited by 55
2A to the Fore – Research, Technology and Applications
Luke, G. A., Escuin-Ordinas, H., de Felipe, P., & Ryan, M. D. (2009) · Biotechnology and Genetic Engineering Reviews · doi:10.5661/bger-26-223 · Cited by 59
“Both preclinical murine models and early clinical studies suggest synergy between CTLA-4 antibody blockade and vaccination with irradiated GM-CSF tumour cells (Hurwitz et al., 2000; Hodi et al., 2003; Quezada et al., 2006).”
BackgroundOvercoming Tumor-Mediated Immunosuppression
Schlößer, H., Theurich, S., Shimabukuro‐Vornhagen, A., Holtick, U., Stippel, D. L., & von Bergwelt‐Baildon, M. (2014) · Immunotherapy · doi:10.2217/imt.14.58 · Cited by 57
Regulatory T cells actively infiltrate metastatic brain tumors
Lesniak (2009) · International Journal of Oncology · doi:10.3892/ijo_00000282 · Cited by 48
Avogadri, F., Zappasodi, R., Yang, A. S., Budhu, S., Malandro, N., Hirschhorn-Cymerman, D., Tiwari, S., Maughan, M. F., Olmsted, R. A., Wolchok, J. D., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0220 · Cited by 52
“mAbs can provide synergistic antitumor activity (4, 13, 14).”
BackgroundLeshem, Y., O'Brien, J., Liu, X., Bera, T. K., Terabe, M., Berzofsky, J. A., Bossenmaier, B., Niederfellner, G. J., Tai, C., Reiter, Y., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0330 · Cited by 49
“Our observations are consistent with previous studies showing that anti–CTLA-4 therapy increases the percentage of tumor-infiltrating CD8þ T cells and depends on this cell subset (23, 24).”
ResultQiu, H. Y., Zmina, P. M., Huang, A. Y.-C., Askew, D., & Bedogni, B. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.024 · Cited by 49
“Given that responses to immune checkpoints inhibitors have been associated to an increase in the CD8 population over Tregs[33], inhibition of Notch1 can potentially improve the efficacy of immune therapies by tipping the scale toward a more immune responsive TME.”
BackgroundTreatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma
Zhang, N., Li, W., Ye, M., Kang, C., & You, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.592612 · Cited by 57
“Tregs can infiltrate various tumor cells (30).”
BackgroundInfluentialDu, T., Shi, G., Li, Y., ZHANG, J. F., Tian, H., Wei, Y., Deng, H., & Yu, D. (2014) · Cancer Gene Therapy · doi:10.1038/cgt.2014.34 · Cited by 55
Vaccination of patients with cutaneous melanoma with telomerase-specific peptides
Hunger, R. E., Lang, K. K., Markowski-Grimsrud, C. J., Trachsel, S., Møller, M., Eriksen, J. A., Rasmussen, A., Braathen, L. R., & Gaudernack, G. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1061-z · Cited by 47
“This may either be achieved by eliminating immunosuppressive mechanisms [ 27 ], enhancing the immune response by a more potent adjuvant or by continued booster vaccination as have been used in other trials [19].”
BackgroundMoore, T. V., Wagner, C. R., Scurti, G. M., Hutchens, K. A., Godellas, C. V., Clark, A. L., Kolawole, E. M., Hellman, L. M., Singh, N. K., Huyke‐Hernández, F. A., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2073-0 · Cited by 50
Modulating Co-Stimulation During Antigen Presentation to Enhance Cancer Immunotherapy
Liechtenstein, T., Dufait, I., Lanna, A., Breckpot, K., & Escors, D. (2012) · Immunology Endocrine & Metabolic Agents - Medicinal Chemistry · doi:10.2174/187152212802001875 · Cited by 58
“Interestingly, CTLA-4 blockade can also be combined with other immunotherapy approaches such as inhibition of inhibitory co-stimulation [178], enhancement of activatory co-stimulation [179, 180], cytokine treatments [181] or superantigens [182].”
BackgroundZhu, Y., Elsheikha, H. M., Wang, J.-H., Fang, S., He, J.-J., Zhu, X.-Q., & Chen, J. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002970 · Cited by 51
Wennerberg, E., Mukherjee, S., Spada, S., Hung, C., Agrusa, C. J., Chen, C., Valeta-Magara, A., Rudqvist, N.-P., Nest, S. J. V., Kamel, M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abe8195 · Cited by 47
“10 of 16 thus skewing the CD8 T cell to CD4 Treg cell ratio, which is associated with immunotherapy response and tumor rejection (38).”
BackgroundYuan, J. D., Page, D. B., Ku, G. Y., Li, Y., Mu, Z., Ariyan, C. E., Gallardo, H. F., Roman, R.-A., Heine, A. I., Terzulli, S. L., et al. (2010) · PubMed · Cited by 50
Tumour heterogeneity and immune-modulation
Jamal‐Hanjani, M., Thanopoulou, E., Peggs, K. S., Quezada, S. A., & Swanton, C. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.04.006 · Cited by 49
“Importantly, immunity to tumour-associated antigens can be potentiated given proper identification and manipulation of immune-regulatory checkpoints restricting T cell function [47,48].”
BackgroundCancer vaccines for established cancer: how to make them better?
Andrews, D. M., Maraskovsky, E., & Smyth, M. J. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00612.x · Cited by 47
“The early promise of antiCTLA-4 combined with GVAX (99, 115, 116) and combination antibody therapies reactive with different arms of cellular immunity (117) demonstrate that an understanding of all of the players is key to the generation of cancer therapies.”
BackgroundmTOR Inhibition Improves Antitumor Effects of Vaccination with Antigen-Encoding RNA
Diken, M., Kreiter, S., Vascotto, F., Selmi, A., Attig, S., Diekmann, J., Huber, C., Türeci, Ö., & Sahin, U. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0046 · Cited by 45
“Results from another study in the B16 melanoma model indicated that not the absolute number of Treg but the ratio of intratumoral CD8þ T cell to Treg (Teff/Treg) is correlated with therapeutic efficacy (25).”
BackgroundSynergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT
Duperret, E. K., Wise, M. C., Trautz, A., Villarreal, D. O., Ferraro, B., Walters, J. N., Yan, J., Khan, A. S., Masteller, E. L., Humeau, L. M. P. F., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.010 · Cited by 45
Tian, J., Guo, F., Zheng, G.-Y., & Ahmad, A. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx141 · Cited by 45
Dendritic Cell-Based Immunotherapy for Solid Tumors
Jung, N.-C., Lee, J.-H., Chung, K., Kwak, Y., & Lim, D. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.03.007 · Cited by 47
Okada, R., Kato, T., Furusawa, A., Inagaki, F. F., Wakiyama, H., Choyke, P. L., & Kobayashi, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000269 · Cited by 48
Okada, R., Furusawa, A., Vermeer, D. W., Inagaki, F. F., Wakiyama, H., Kato, T., Nagaya, T., Choyke, P. L., Spanos, W. C., Allen, C. T., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103345 · Cited by 48
“In these two groups, intratumoral CD4Foxp3 Tregs were successfully depleted from CD3 T cells, resulting in increased CD4 non-Treg/Treg ratio and CD8/Treg ratio, which are known to be an indicator of robust antitumor immune response [18,19].”
BackgroundWang, H.-T., Lee, H., Guo, J., Chen, S., Liao, Z., Huang, K., Torng, P., & Hwang, L. (2011) · International Journal of Cancer · doi:10.1002/ijc.26339 · Cited by 44
“However, it has been previously demonstrated that an increased effector/Treg ratio in the tumor microenvironment can result in improved antitumor effects.(46,47) To increase this ratio, the tumor environment can be modulated to decrease the number of local Tregs or tolerant T cells and/ or to increase the number of ef…”
BackgroundMocellin, S., & Nitti, D. (2007) · Medicinal Research Reviews · doi:10.1002/med.20110 · Cited by 47
Chang, L.-Y., Lin, Y., Kang, C.-W., Hsu, C.-Y., Chu, Y., Huang, C., Day, Y., Chen, T., Yeh, C., & Lin, C. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200266 · Cited by 50
Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity
Bakhru, P., Zhu, M., Wang, H., Hong, L. K., Khan, I. S., Mouchess, M. L., Gulati, A., Starmer, J., Hou, Y., Sailer, D., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93265 · Cited by 45
“aCTLA-4 antibody treatment has been reported to have pleiotropic effects on T cells, which include intratumoral Treg depletion and promoting increased Teff/Treg ratios (18, 22, 38, 39).”
BackgroundSharma, P., Sohn, J., Shin, S. J., Oh, D., Keam, B., Lee, H. J., Gizzi, M., Kalinka‐Warzocha, E., Vos, F. D., Ruscica, D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1635 · Cited by 46
Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma
Wang, X., Zuo, D., Sarkar, D., & Fisher, P. B. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.629187 · Cited by 46
“Recent studies showed that the combination of CTLA-4 blockade with a GM-CSF-transduced melanoma cell vaccine induced a greater intratumoral ratio of Teff to Treg, which directly correlated with tumor rejection [80].”
BackgroundIntegrative Characterization of the Role of IL27 In Melanoma Using Bioinformatics Analysis
Dong, C., Dang, D., Zhao, X., Wang, Y., Wang, Z., & Zhang, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.713001 · Cited by 42
“The CD8 T cell to regulatory T cell (CD8/Treg) ratio is predictive of the therapeutic efficacy of the immunotherapy (43).”
BackgroundG Protein-Coupled Receptor 83 Is Dispensable for the Development and Function of Regulatory T Cells
Lu, L., Gavin, M. A., Rasmussen, J. P., & Rudensky, A. Y. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01075-07 · Cited by 40
“These tumor-induced Treg cells were shown to accumulate within the tumor as well as in the tumor-draining LNs and were implicated in the attenuation of antitumor immune responses (3, 19).”
BackgroundLuo, W., Yang, G., Luo, W., Cao, Z., Liu, Y., Qiu, J., Chen, G., You, L., Zhao, F., Zheng, L., et al. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1147-9 · Cited by 45
T regulatory cells, the evolution of targeted immunotherapy
Nizar, S. A., Meyer, B., Galustian, C., Kumar, D., & Dalgleish, A. G. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.02.001 · Cited by 50
Fang, J., Hu, B., Li, S., Zhang, C., Liu, Y., & Wang, P. (2016) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2016.7 · Cited by 43
Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy
Zhang, J., Liu, D., Li, G., Staveley-O’Carroll, K. F., Graff, J. N., Li, Z., & Wu, J. D. (2017) · Science Advances · doi:10.1126/sciadv.1602133 · Cited by 40
Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy
Rizk, E. M., Gartrell, R. D., Barker, L. W., Esancy, C. L., Finkel, G. G., Bordbar, D. D., & Saenger, Y. M. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.12.005 · Cited by 47
Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy
Li, B., VanRoey, M. J., & Jooss, K. U. (2007) · Clinical Immunology · doi:10.1016/j.clim.2007.01.002 · Cited by 41
Liu, Y., Peng, Y., Mi, M., Guevara-Patino, J. A., Munn, D. H., Fu, N., & He, Y. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900008 · Cited by 45
“Previous reports have shown that both the GM-CSF B16 tumor vaccine (GVAX) and CTLA4 blockade are required to increase CD8 T cell infiltration into small B16 tumor (39); with more established tumor, a combination of vaccines, CTLA4 blockade, and prophylactic depletion of Treg is needed to enhance tumor CD8 T cell infil…”
ResultSrivastava, A. K., Dinc, G., Sharma, R. K., Yolcu, E. S., Zhao, H., & Shirwan, H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1768-a · Cited by 43
“We next tested whether decrease in the number of Treg cells caused by SA-4-1BBL/MPL or SA-4-1BBL as monotherapy inversely correlates with the number of intratumoral CD8þ T cells, a hallmark of successful immunotherapeutic approach against cancer (26).”
Prioritization schema for immunotherapy clinical trials in glioblastoma
Hodges, T. R., Ferguson, S. D., Caruso, H. G., Kohanbash, G., Zhou, S., Cloughesy, T. F., Berger, M. S., Poste, G. H., Khasraw, M., Ba, S., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1145332 · Cited by 41
Viral hepatitis, inflammation, and cancer: A lesson for autoimmunity
Piconese, S., Cammarata, I., & Barnaba, V. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.10.021 · Cited by 44
Relecom, A., Merhi, M., Inchakalody, V. P., Shahab Uddin, M. S., Rinchai, D., Bedognetti, D., & Dermime, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01872-3 · Cited by 44
“In line with this, an on-treatment increase in intratumoral Teff:Treg ratio conditions optimal immune control of the tumor under anti-CTLA-4 in a number of models [77, 78, 80, 85].”
BackgroundKoske, I., Rössler, A., Pipperger, L., Petersson, M., Barnstorf, I., Kimpel, J., Tripp, C. H., Stoitzner, P., Bánki, Z., & von Laer, D. (2019) · International Journal of Cancer · doi:10.1002/ijc.32325 · Cited by 43
Self-assembling peptides as immunomodulatory biomaterials
Hernández, A., Hartgerink, J. D., & Young, S. W. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1139782 · Cited by 39
“For instance, there have been early reports of combining anti-CTLA-4 with immunostimulatory substances such as GM-CSF, anti-CD25, and anti-CD40 (van Elsas et al., 1999; Sutmuller et al., 2001; Quezada et al., 2006; Sorensen et al., 2010).”
BackgroundMechanisms of Resistance to Checkpoint Blockade Therapy
Shi, H., Lan, J., & Yang, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_5 · Cited by 40
Biology and Clinical Observations of Regulatory T Cells in Cancer Immunology
Teng, M. W. L., Ritchie, D. S., Neeson, P. J., & Smyth, M. J. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_50 · Cited by 37
Frijlink, E., Bosma, D. M. T., Busselaar, J., Battaglia, T., Staal, M. D., Verbrugge, I., & Borst, J. G. (2024) · Journal of Clinical Investigation · doi:10.1172/jci171154 · Cited by 46
“CTLA-4 blockade efficacy is known to largely rely on a high CTL over Treg ratio in the tumor (77, 78).”
Akins, E. J., Moore, M. L., Tang, S., Willingham, M. C., Tooze, J. A., & Dubey, P. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2490 · Cited by 40
“The ratio of CD8+ to FoxP3+ T cells within the tumor is a prognostic indicator of immune efficacy (20, 36, 37).”
BackgroundPhosphoinositide 3‐kinase δ is a regulatory T‐cell target in cancer immunotherapy
Lim, E. L., & Okkenhaug, K. (2019) · Immunology · doi:10.1111/imm.13082 · Cited by 43
Cancer Resistance to Immunotherapy: Molecular Mechanisms and Tackling Strategies
Vu, S. H., Vetrivel, P., Kim, J., & Lee, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810906 · Cited by 45
“Upon anti-CTLA-4 mAb treatment, the ratio of Teffs to Tregs was positively associated with treatment response, which is dependent on the presence of Fcγ receptor-expressing macrophages [58,59], suggesting the use of anti-CTLA4 antibodies with enhanced FcγR binding profiles to achieve robust anti-tumor responses and im…”
BackgroundAshoub, M. H., Razavi, R., Heydaryan, K., Salavati‐Niasari, M., & Amiri, M. (2024) · European journal of medical research · doi:10.1186/s40001-024-01822-7 · Cited by 39
“According to Quezada et al., the proportion of effector T cells to Tregs in the TME was associated with the outcome of anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) immunotherapy [242].”
BackgroundMechanism‐based treatment of cancer with immune checkpoint inhibitor therapies
Abdou, Y. G., Pandey, M. R., Sarma, M., Shah, S., Baron, J. I., & Ernstoff, M. S. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14316 · Cited by 36
“Other strategies include combination of anti-CTLA-4 with granulocyte-macrophage colony-stimulating factor (GM-CSF) through GMCSF transduced vaccine (Gvax).(29) This combination was thought to attract immune cells into the tumour environment, change the intratumour balance of CD4 Tregs and CD8 effector T-cells, and lea…”
MethodImmune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development
Kiaie, S. H., Sanaei, M. J., Heshmati, M., Asadzadeh, Z., Azimi, I., Hadidi, S., Jafari, R., & Baradaran, B. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.12.011 · Cited by 36
Defining Immunogenic and Radioimmunogenic Tumors
Medler, T. R., Blair, T. C., Crittenden, M. R., & Gough, M. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.667075 · Cited by 40
Dobrzanski, M. J., Rewers‐Felkins, K., Quinlin, I. S., Samad, K. A., Phillips, C. A., Robinson, W., Dobrzanski, D. J., & Wright, S. E. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.08.007 · Cited by 40
Abatacept therapy and safety management
Pham, T., Claudepierre, P., Constantin, A., Fautrel, B., Gossec, L., Gottenberg, J., Goupille, P., HACHULLA, E., Masson, C., Morel, J., et al. (2009) · Joint Bone Spine · doi:10.1016/s1297-319x(09)74520-8 · Cited by 40
Ali, O. A., Doherty, E. J., Mooney, D. J., & Emerich, D. F. (2011) · Biomatter · doi:10.4161/biom.1.1.16277 · Cited by 41
Rational combination immunotherapeutic approaches for effective cancer treatment
Phung, C. D., Nguyen, H. T., Tran, T. H., Choi, H., Yong, C. S., & Kim, J. O. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.020 · Cited by 36
Wang, Y., Li, P., Mao, S., Mo, Z., Cao, Z., Luo, J., Zhou, M., Liu, X., Zhang, S., & Yu, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.757194 · Cited by 36
Targets of Protective Tumor Immunity
Dranoff, G. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04938.x · Cited by 36
Foy, S. P., Mandl, S. J., Cruz, T. D., Cote, J. J., Gordon, E. J., Trent, E., Delcayre, A. X., Breitmeyer, J. B., Franzusoff, A., & Rountree, R. B. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1816-7 · Cited by 41
“Unlike earlier reports, the Teff/Treg ratio did not increase following CTLA-4 inhibition alone [30–32], even though Fo xP 3 + IC O S +”
BackgroundCheckpoint blockade in combination with cancer vaccines
Morse, M. A., & Lyerly, H. K. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.10.057 · Cited by 35
Miller, C. L., Sagiv-Barfi, I., Neuhöfer, P., Czerwinski, D. K., Artandi, S. E., Bertozzi, C. R., Levy, R., & Cochran, J. R. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.10.012 · Cited by 36
Wall, E. M., Milne, K., Martin, M. L., Watson, P. H., Theiss, P. M., & Nelson, B. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0622 · Cited by 41
Regulatory T cell-mediated suppression: potential role of ICER
Bodor, J., Fehervari, Z. T., Diamond, B., & Sakaguchi, S. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0706474 · Cited by 40
“3B) and thus, interfere with TR cell function [36, 72, 74, 75].”
BackgroundMechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy
Lee, J., & Kim, E. H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1233376 · Cited by 39
“The anti-tumor effects of CTLA-4 blockade have been shown to be accompanied by an increase in effector T cells and a decrease in Tregs, thereby leading to an elevated ratio of intratumoral effector T cells to Tregs in mouse tumor models (15, 16).”
BackgroundGut Microbiota and the Paradox of Cancer Immunotherapy
Poutahidis, T., Kleinewietfeld, M., & Erdman, S. E. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00157 · Cited by 34
“However, a similar regimen could lead to an opposite effect with the accumulation of TREG and CD8 T-cells in tumors (27, 28).”
BackgroundAptamers: A New Technological Platform in Cancer Immunotherapy
Pastor, F. (2016) · Pharmaceuticals · doi:10.3390/ph9040064 · Cited by 33
“The use of irradiated whole-cell vaccines genetically engineered to express immunostimulatory molecules has shown very promising results in preclinical settings, as they are able to elicit an immune response against the specific tumor antigens expressed in the tumor [67].”
BackgroundTissue‐specific tumor microenvironments influence responses to immunotherapies
Oliver, A. J., Davey, A. S., Keam, S. P., Mardiana, S., Chan, J. D., von Scheidt, B., Beavis, P. A., House, I. G., Audenaerde, J. R. M. V., Darcy, P. K., et al. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1094 · Cited by 38
“8,9 Therefore, outcomes of immunotherapies are not restricted by the tumor cells themselves, and consideration of the TME is vital for optimal immunotherapies.”
Kato, T., Okada, R., Furusawa, A., Inagaki, F. F., Wakiyama, H., Furumoto, H., Okuyama, S., Fukushima, H., Choyke, P. L., & Kobayashi, H. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0470 · Cited by 39
“Next, we evaluated the CD8þ/CD4þFoxP3þ (Treg) ratio of TILs, because this ratio is known to be an indicator of a robust antitumor immune response (33).”
MethodLin, X., Chen, H., Xie, Y., Zhou, X. M., Wang, Y., Zhou, J., Long, S., Hu, Z., Zhang, S., Qiu, W., et al. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101298 · Cited by 37
“When CTLA-4 blockade is combined with melanoma cell vaccine, the ratio of effector T cells (Teff)/Treg induced in tumor is larger, which is directly associated with tumor rejection [36].”
BackgroundZhang, W., Song, Z., Xiao, J., Liu, X., Luo, Y., Yang, Z., Luo, R., & Li, A. (2019) · Journal of Cancer · doi:10.7150/jca.26961 · Cited by 33
“Researchers have investigated factors that influence the efficacy of DC-CIK cells and the exhaustion of T cells, and agents that can optimize the tumor microenvironment to stimulate immune responses, including those that target immune checkpoints molecules like PD-1, have been administered to CIK cells [28, 29].”
BackgroundGe, Y., Zhang, Y., Zhao, K., & Zhu, H. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s374672 · Cited by 34
“Therefore, dual blockade of PD-1 and CTLA-4 induces an improved frequency of effector CD8 and CD4 T cells in the tumor, resulting in an increased ratio of CD8 T cell to Treg (regulatory T cell) and CD4 T cell to Treg ratio, which correlates with high antitumor activity.(40,43,44) Collectively, these findings support t…”
Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma
Peggs, K. S., & Quezada, S. A. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.144 · Cited by 39
Metadata
- Authors
- Quezada, S. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Quezada, S. A.
- ORCID
- Quezada, S. A.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-07-03
- Volume
- 116
- Issue
- 7
- Pages
- 1935-1945
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1479425
- OpenAlex
- W2131874142
- Cited by
- 700
- References
- 50
- Citations by year
- 2026: 12 · 2025: 14 · 2024: 22 · 2023: 37 · 2022: 31 · 2021: 44 · 2020: 35 · 2019: 37 · 2018: 41 · 2017: 46 · 2016: 29 · 2015: 41 · 2014: 41 · 2013: 39 · 2012: 38
- FWCI
- 18.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Cancer Research Institute
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4 blockade, GM-CSF, GVAX, tumor cell vaccine, regulatory T cells, effector T cells, B16-BL6 melanoma, antitumor immunity, Foxp3, CD8+ T cells, CD4+ T cells, tumor rejection, combination immunotherapy
- MeSH terms
- Animals, Antigens, Differentiation, Immunotherapy, Lymph Nodes, Melanoma, Experimental, Mice, Inbred C57BL, Antigens, CD, CD4 Antigens, T-Lymphocyte Subsets, Granulocyte-Macrophage Colony-Stimulating Factor, CD8 Antigens, Cancer Vaccines, Cell Line, Tumor, Cell Proliferation, T-Lymphocytes, Regulatory, Mice, Forkhead Transcription Factors, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.